Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats.

Ma Y, Zhan M, OuYang L, Li Y, Chen S, Wu J, Chen J, Luo C, Lei W.

Behav Brain Res. 2014 Jun 1;266:37-45. doi: 10.1016/j.bbr.2014.02.039. Epub 2014 Mar 5.

PMID:
24613235
2.

Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.

Yuan H, Sarre S, Ebinger G, Michotte Y.

J Neurosci Methods. 2005 May 15;144(1):35-45. Epub 2004 Dec 8.

PMID:
15848237
3.

EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.

Vorobyov VV, Schibaev NV, Morelli M, Carta AR.

Brain Res. 2003 May 16;972(1-2):177-85.

PMID:
12711091
4.

The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.

Bagga V, Dunnett SB, Fricker RA.

Behav Brain Res. 2015 Jul 15;288:107-17. doi: 10.1016/j.bbr.2015.03.058. Epub 2015 Apr 2.

PMID:
25841616
5.

Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.

Iancu R, Mohapel P, Brundin P, Paul G.

Behav Brain Res. 2005 Jul 1;162(1):1-10.

PMID:
15922062
6.
7.

Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.

Sindhu KM, Banerjee R, Senthilkumar KS, Saravanan KS, Raju BC, Rao JM, Mohanakumar KP.

Pharmacol Biochem Behav. 2006 Jun;84(2):321-9. Epub 2006 Jul 3.

PMID:
16820197
8.

Nigral 6-hydroxydopamine lesion impairs performance in a lateralised choice reaction time task--impact of training and task parameters.

Lindgren HS, Klein A, Dunnett SB.

Behav Brain Res. 2014 Jun 1;266:207-15. doi: 10.1016/j.bbr.2014.02.043. Epub 2014 Mar 5.

PMID:
24613237
10.

A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.

Han B, Jin HJ, Song MY, Wang T, Zhao H.

Parkinsonism Relat Disord. 2014 Nov;20(11):1191-5. doi: 10.1016/j.parkreldis.2014.08.022. Epub 2014 Sep 1.

PMID:
25219971
11.

Short- and long-term unilateral 6-hydroxydopamine lesions in rats show different changes in characteristics of spontaneous firing of substantia nigra pars reticulata neurons.

Seeger-Armbruster S, von Ameln-Mayerhofer A.

Exp Brain Res. 2013 Jan;224(1):15-24. doi: 10.1007/s00221-012-3285-3. Epub 2012 Oct 9.

PMID:
23283416
12.

Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.

Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN.

Neuroscience. 2008 Oct 28;156(4):830-40. doi: 10.1016/j.neuroscience.2008.08.035. Epub 2008 Sep 9.

PMID:
18817851
13.

Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA.

Neurobiol Dis. 2011 Jun;42(3):327-40. doi: 10.1016/j.nbd.2011.01.024. Epub 2011 Feb 19.

PMID:
21310234
14.

Opposite effects of intranigral ibotenic acid and 6-hydroxydopamine on motor behavior and on striatal neuropeptide Y neurons.

Nitsch C, Wolfrum G, Schaefer F, Scotti AL, Unger J.

Brain Res Bull. 1993;30(1-2):21-32.

PMID:
8420631
15.

Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.

Warraich ST, Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, Henderson JM.

Brain Res Bull. 2009 Feb 16;78(2-3):85-90. doi: 10.1016/j.brainresbull.2008.08.023. Epub 2008 Sep 24.

PMID:
18822357
16.

Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.

Yin LH, Shen H, Diaz-Ruiz O, B├Ąckman CM, Bae E, Yu SJ, Wang Y.

BMC Neurosci. 2012 Oct 6;13:120. doi: 10.1186/1471-2202-13-120.

18.

Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine.

Suzuki K, Okada K, Wakuda T, Shinmura C, Kameno Y, Iwata K, Takahashi T, Suda S, Matsuzaki H, Iwata Y, Hashimoto K, Mori N.

PLoS One. 2010 Feb 17;5(2):e9260. doi: 10.1371/journal.pone.0009260.

19.

Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease.

Henning J, Strauss U, Wree A, Gimsa J, Rolfs A, Benecke R, Gimsa U.

Neurosci Res. 2008 Dec;62(4):246-53. doi: 10.1016/j.neures.2008.09.001. Epub 2008 Sep 7.

PMID:
18824050
20.

A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.

Boix J, Padel T, Paul G.

Behav Brain Res. 2015 May 1;284:196-206. doi: 10.1016/j.bbr.2015.01.053. Epub 2015 Feb 16.

Supplemental Content

Support Center